Medical Management

Direct Oral Anticoagulants: A Quick Guide

For more than 50 years, oral vitamin K antagonists (VKAs) were the choice of anticoagulant for the long-term treatment and prevention of arterial and venous thromboembolic events (VTE). VKA treatment is safe and effective, if a high time in therapeutic range is achieved. However, achieving a stable, therapeutic international normalised ratio can prove challenging in the context of drug and food interactions and liver disease, resulting in either an increased risk of thromboembolism due to undertreatment or bleeding due to overtreatment.